Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Martina Hansen's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04303026
- Locations
- 🇳🇴
Martina Hansens Hospital, Sandvika, Norway
Bisphosphonates for the Treatment of Seropositive Musculoskeletal Complaints
- Conditions
- Seropositive Muskuloskeletal Complaints
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 80
- Registration Number
- NCT04115397
Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery
- Conditions
- Bariatric Surgery CandidateBone Loss
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT04087096
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Osteoporosis in Primary Hyperparathyroidism
- Conditions
- Primary HyperparathyroidismOsteoporosis
- Interventions
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 40
- Registration Number
- NCT04085419
- Locations
- 🇸🇮
Endocrinology Department, Ljubljana, Slovenia
Study on Bisphosphonates Targeting Triple-negative Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04045522
- Locations
- 🇨🇳
People's Hospital of Liaoning Province, Shenyang, Liaoning, China
🇨🇳Liaoning Tumor Hospital & Institute, Shenyang, Liaoning, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid
- Conditions
- Idiopathic Inflammatory MyopathiesOsteoporosis, Osteopenia
- Interventions
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Kwong Wah Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04034199
- Locations
- 🇭🇰
Kwong Wah Hospital, Hong Kong, Hong Kong
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 150
- Registration Number
- NCT03932071
- Locations
- 🇨🇳
2nd Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Denosumab Sequential Therapy
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 101
- Registration Number
- NCT03868033
- Locations
- 🇨🇳
Department of Orthopedics, National Taiwan University Hospital, Taipei, N/A = Not Applicable, Taiwan
Zoledronic Acid in Combination With Interleukin-2 to Expand Vγ9Vδ2 T Cells After T-replete Haplo-identical Allotransplant
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03862833
- Locations
- 🇫🇷
Nantes Uh, Nantes, France
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
- Conditions
- Osteogenesis Imperfecta
- Interventions
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 380
- Registration Number
- NCT03735537
- Locations
- 🇬🇧
Bristol Royal Infirmary, Bristol, United Kingdom
🇮🇪St Vincent's Hospital, Dublin, Ireland
🇬🇧Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.